Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fludarabine + cyclophosphamide + doxorubicin + rituximab
- Development stage
- Unknown
- Lead developer
- Bayer
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral, Subcutaneous
01
Overview
A combination chemotherapy regimen consisting of fludarabine (a purine analog), cyclophosphamide (an alkylating agent), doxorubicin (an anthracycline antibiotic), and rituximab (a monoclonal anti-CD20 antibody). While the three-drug combination of fludarabine, cyclophosphamide, and rituximab (FCR) is well-established for treating chronic lymphocytic leukemia and mantle cell lymphoma, the specific four-drug combination including doxorubicin is not commonly documented in standard treatment protocols.
02
Targets
CD20 (B-lymphocyte antigen CD20)RNR (Ribonucleotide reductase)DNA polymerase familyTOP2A (DNA topoisomerase II)DNA
Beyond the preview
Go deeper on fludarabine + cyclophosphamide + doxorubicin + rituximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fludarabine + cyclophosphamide + doxorubicin + rituximab.